"Robert's significant US management and development experience in the biotechnology industry combined with strong ties with US venture capitalists and general investors will be critical to our future growth strategy," said Progen's CEO, Justus Homburg. "He has been involved in various aspects of the biotech business, including playing a key role in our acquisition of CellGate, and we look forward to utilizing his expertise for our continued corporate development."
Mr. Homburg added, "With such a suitably qualified and experienced Board, I am even more excited about the Company's future prospects of becoming a globally competitive biotechnology company centered on our lead compound PI-88, supplemented by the new very exciting portfolio of compounds acquired through the Cellgate acquisition which are all in early stages of clinical and preclinical development."
Further details on the qualifications and experience on the three board appointments follow:
Mr. John Lee
Mr. Lee founded Stockholder Relations, an Australian-based management consultancy specializing in corporate advisory, investor relations and corporate governance, in 1987. He has considerable experience in providing strategic and operational advice to companies in their dealings with institutional investors, stockbrokers, shareholders, financiers, and the financial media.
Currently, Mr. Lee is a non-executive Chairman of Portland Orthopedics Limited (PLD), developer, manufacturer and distributor of a range of reconstructive orthopaedic devices; non-executive Chairman of Milvella Limited, a medical device company focused on the development and delivery of single-use surgical devices that optimize the results of intraocular procedures; and a non-executive director of TMG International Pty Ltd, which provides specialist consulting services and technologies to the rail industry.
Mr. Robert Williamson
|SOURCE Progen Pharmaceuticals Limited|
Copyright©2008 PR Newswire.
All rights reserved